Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 5/20 | 0.36 |
| ▸ | MMP9 | P14780 | 5/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1108484 | 1.00 | MMP1 (0.44) | MMP1CXCR4PGRMEN1KMT2A | |
| SCHEMBL1108518 | 0.93 | MMP1 (0.50) | MMP1CXCR4PGRMEN1KMT2A | |
| SCHEMBL1100869 | 0.93 | MMP1 (0.50) | MMP1CXCR4PGRMEN1KMT2A | |
| SCHEMBL7138391 | 0.89 | MMP1 (0.42) | MMP1PGRMEN1KMT2ABCL2L1 | |
| SCHEMBL1101192 | 0.88 | LGALS8 (0.41) | MMP1CXCR4PGRMEN1KMT2A | |
| SCHEMBL1108527 | 0.85 | ALDH1A1 (0.48) | MMP1CXCR4PGRMEN1KMT2A | |
| SCHEMBL13126968 | 0.85 | CXCR4 (0.43) | MMP1CXCR4MEN1KMT2ALMNA | |
| SCHEMBL7135320 | 0.85 | ALDH1A1 (0.44) | MMP1CXCR4MEN1KMT2ALMNA | |
| SCHEMBL1100132 | 0.85 | ALDH1A1 (0.48) | MMP1CXCR4PGRMEN1KMT2A | |
| SCHEMBL1100111 | 0.84 | PGR (0.42) | MMP1PGRMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| EP-1370537-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | MMP1 8/4885CXCR4 2779/4885PGR 3527/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | MMP1 8/4885CXCR4 2779/4885PGR 3527/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | MMP1 11/4885CXCR4 3197/4885PGR 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.